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Megalin and  
renal injury
Currently, there is little doubt that pro-
teinuria is one of the major causes of 
renal inflammatory injury, which causes 
tubulointerstitial damage. Filtration of 
albumin is followed by its absorption 
into the proximal tubule, where it is 
endocytosed and delivered to the lyso-
somes for degradation. The major albu-
min receptor is megalin. To ascertain the 
role of the endocytic pathway in inflam-
mation, Motoyoshi et al. studied mice 
that had a mosaic deletion of megalin 
in the proximal tubule. In this mouse 
model, some of the proximal tubules 
had megalin, whereas neighboring 
nephrons had deletions in the gene, pro-
viding an ideal assessment of its role in 
the same kidneys. The authors induced 
proteinuria in these mice and com-
pared megalin-containing tubules with 
those lacking this receptor. They found, 
as expected, that the megalin-deleted 
tubules did not absorb filtered albumin. 
The tubules that expressed megalin (and 
absorbed filtered proteins) expressed 
many inflammatory markers, includ-
ing heme-oxygenase-1 and monocyte 
chemoattractant protein-1. These cells 
also preferentially developed apoptosis. 
These results demonstrate that megalin 
is the critical agent and first step in the 
pathway that leads to the inflammatory 
cascade in renal injury once it binds 
to albumin and causes its endocytosis. 
See page 1262.
Cinacalcet suppresses 
vascular calcification
Calcimimetics, such as cinacalcet, have 
been shown to effectively reduce the 
levels of parathyroid hormone (PTH) in 
patients with renal disease. They are now 
routinely used in the treatment of sec-
ondary hyperparathyroidism. Among the 
major problems in end-stage renal disease 
is metastatic calcification, especially that 
seen in blood vessels. In a study described 
in this issue, Kawata et al. induced severe 
renal disease in rats who were fed high-
phosphate diets. These animals developed 
calcification of the smooth muscles of 
their aortae. The authors also found that 
the expression of the osteoblastic line-
age genes osteocalcin, osteopontin, and 
Runx2 was also increased. When these 
animals were treated with cinacalcet, 
calcification was suppressed, as was the 
level of PTH, calcium, phosphorus, and 
the calcium-phosphorus product. These 
studies show that reduction of PTH in 
hyperphosphatemic uremia could limit 
vascular calcification, which is now 
known to be a major risk factor for death 
in patients with end-stage renal disease. 
See page 1270.
Dendritic cells secrete 
proinflammatory 
mediators during 
obstruction
Acute obstruction leads to inflamma-
tion, which is produced in large part 
by invasion of the kidney with leuko-
cyte accumulation and the secretion of 
inflammatory mediators. Now, Dong et 
al. show that induced unilateral ureteral 
ligation causes a progressive increase 
in renal F4/80+ and F4/80– dendritic 
cells, monocytes, neutrophils, and T 
cells. When the investigators depleted 
dendritic cells, the amount of tumor 
necrosis factor and other proinflamma-
tory mediators was notably reduced. In 
obstructed kidneys, dendritic cells local-
ized to the cortico-medullary junction 
and to the cortex. When T cells were 
isolated from obstructed kidneys and 
analyzed for their cytokine expression, 
they were found to secrete interferon-γ, 
usually found in CD4+ and CD8+ mem-
ory T cells as well as interleukin-17 (IL-
17)-secreting CD4+ memory T cells. The 
authors then attempted to deplete intra-
renal dendritic cells before obstructing 
the ureter. While the number of 
T cells did not change, the number of 
interferon-γ- and IL-17-competent 
T cells was reduced. These results demon-
strate that dendritic cells induce inflam-
mation during obstruction by producing 
proinflammatory mediators, which then 
recruit and activate effector-memory 
T cells, including IL-17-secreting CD4+ 
T cells. See page 1294.
